Compare Phillips 66 (PSX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Smith & Nephew plc — how do they compare? Phillips 66 trades at $279.5 (market cap $112.36B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Phillips 66 is far larger — about 10.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and Smith & Nephew plc for 120 Days on average.
| PSX | SNN | |
|---|---|---|
Market Cap | $112.36B | $11.10B |
Volume | 2,374,751 | 1,051,703 |
Sector | Energy | Health |
52-Week High | $281.60 | $37.17 |
52-Week Low | $126.76 | $26.42 |
Typical Hold Time | 62 Days | 120 Days |
Enterprise Value | $128.83B | $14.13B |
Dividend Yield | 1.8% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSX trades at $271.62, up 0.68% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $279. The stock has beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue declined to $132.38B in 2025, but net income improved to $4.40B, and 2026 projections show a rebound to $152.2B revenue and $7.1B net income. The company maintains a solid balance sheet with $72.58B in total assets and recently announced a $1.27 dividend for H2-2026.
The outlook for PSX is positive, supported by structural refining margins and AI-driven operational efficiencies. Investment opportunities include potential price appreciation toward the $279 consensus target and a sustainable dividend. Risks include exposure to volatile oil prices, regulatory changes such as potential diesel export bans, and execution challenges in maintaining profitability amid shifting energy demand.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
